Type 2 diabetes mellitus (T2DM) is currently one of the most prevalent diseases, with as
many as 415 million patients worldwide. T2DM is characterized by elevated blood glucose …

An increasing array of anti-diabetic drugs are available today, yet Type-2 diabetes mellitus
(T2DM)–remains a life threatening disease, causing high mortality and morbidity in …

Aim Preclinical data suggest that treatment with either glucagon-like peptide (GLP)-1
receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors could change the intestinal …

Regulatory peptides produced in islet and gut endocrine cells, including glucagon, glucagon-
like peptide-1 (GLP-1), GLP-2, and glucose-dependent insulinotropic polypeptide, exert …

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been highly
recommended for glycemic control and weight reduction. However, evidence has …

Sarcopenia, or the age‐related loss of skeletal muscle mass and function, is an increasingly
prevalent condition that contributes to reduced quality of life, morbidity, and mortality in older …

The gastrointestinal hormone glucagon‐like peptide‐1 (GLP‐1) lowers postprandial glucose
concentrations by regulating pancreatic islet‐cell function, with stimulation of glucose …

There is increasing evidence that skeletal muscle microvascular (capillary) blood flow plays
an important role in glucose metabolism by increasing the delivery of glucose and insulin to …

Cardiovascular disease is a common co-morbidity and leading cause of death in patients
with type 2 diabetes mellitus (T2DM). Glucagon-like peptide 1 (GLP-1) is a peptide hormone …

Insulin resistance of peripheral muscle is implicated in the etiology of metabolic syndrome in
obesity. Although accumulation of glycerolipids, such as triacylglycerol and diacylglycerol …